330 related articles for article (PubMed ID: 19773755)
1. Mutant p53 mediates survival of breast cancer cells.
Lim LY; Vidnovic N; Ellisen LW; Leong CO
Br J Cancer; 2009 Nov; 101(9):1606-12. PubMed ID: 19773755
[TBL] [Abstract][Full Text] [Related]
2. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.
Tiwary R; Yu W; Sanders BG; Kline K
Breast Cancer Res; 2011 Jan; 13(1):R1. PubMed ID: 21214929
[TBL] [Abstract][Full Text] [Related]
3. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
4. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.
Dohn M; Jiang J; Chen X
Oncogene; 2001 Oct; 20(45):6503-15. PubMed ID: 11641774
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells.
Santag S; Jäger W; Karsten CB; Kati S; Pietrek M; Steinemann D; Sarek G; Ojala PM; Schulz TF
Oncogene; 2013 Aug; 32(32):3676-85. PubMed ID: 22964633
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
DeYoung MP; Johannessen CM; Leong CO; Faquin W; Rocco JW; Ellisen LW
Cancer Res; 2006 Oct; 66(19):9362-8. PubMed ID: 17018588
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
[TBL] [Abstract][Full Text] [Related]
9. The C terminus of p53 family proteins is a cell fate determinant.
Harms KL; Chen X
Mol Cell Biol; 2005 Mar; 25(5):2014-30. PubMed ID: 15713654
[TBL] [Abstract][Full Text] [Related]
10. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
11. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.
Leong CO; Vidnovic N; DeYoung MP; Sgroi D; Ellisen LW
J Clin Invest; 2007 May; 117(5):1370-80. PubMed ID: 17446929
[TBL] [Abstract][Full Text] [Related]
12. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic roles of p53 mutants in mouse models.
Lozano G
Curr Opin Genet Dev; 2007 Feb; 17(1):66-70. PubMed ID: 17208429
[TBL] [Abstract][Full Text] [Related]
14. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor.
Jung MS; Yun J; Chae HD; Kim JM; Kim SC; Choi TS; Shin DY
Oncogene; 2001 Sep; 20(41):5818-25. PubMed ID: 11593387
[TBL] [Abstract][Full Text] [Related]
15. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells.
Nahor I; Abramovitch S; Engeland K; Werner H
Growth Horm IGF Res; 2005 Dec; 15(6):388-96. PubMed ID: 16181796
[TBL] [Abstract][Full Text] [Related]
16. P63 and P73: P53 mimics, menaces and more.
Yang A; McKeon F
Nat Rev Mol Cell Biol; 2000 Dec; 1(3):199-207. PubMed ID: 11252895
[TBL] [Abstract][Full Text] [Related]
17. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
Di Como CJ; Gaiddon C; Prives C
Mol Cell Biol; 1999 Feb; 19(2):1438-49. PubMed ID: 9891077
[TBL] [Abstract][Full Text] [Related]
18. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells.
Senoo M; Manis JP; Alt FW; McKeon F
Cancer Cell; 2004 Jul; 6(1):85-9. PubMed ID: 15261144
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
20. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Li Y; Prives C
Oncogene; 2007 Apr; 26(15):2220-5. PubMed ID: 17401431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
